Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neoadjuvant therapy-Sun Yat-sen University-non-small cell lung cancer
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This is a multi-modality treatment regimen for locally advanced non-small cell lung cancer (NSCLC) being evaluated in a Phase II study led by Sun Yat-sen University. The regimen centers on the use of **iparomlimab and tuvonralimab (QL1706)**, a first-in-class bifunctional antibody (MabPair) that simultaneously targets Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4). In the neoadjuvant phase, QL1706 is combined with bevacizumab (an anti-VEGF antibody), thymosin alpha 1 (an immune modulator), and platinum-based chemotherapy (cisplatin with either albumin-bound paclitaxel or pemetrexed). This is followed by concurrent chemoradiotherapy and a consolidation phase involving QL1706, surufatinib (a VEGFR/FGFR/CSF-1R inhibitor), and thymosin alpha 1. The regimen aims to enhance pathological complete response rates and improve long-term survival in patients with stage III NSCLC.
- Other names
- Dual Immune Checkpoint Blockade in Locally Advanced NSCLC
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)CSF1R (Macrophage colony-stimulating factor receptor)DNADHFR (Dihydrofolate reductase)FGFR (FGFR family)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)VEGFR (VEGFR family)
Beyond the preview
Go deeper on neoadjuvant therapy-Sun Yat-sen University-non-small cell lung cancer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neoadjuvant therapy-Sun Yat-sen University-non-small cell lung cancer.